Clinical attribute | Statistical test | P-value | Q-value |
---|---|---|---|
Somatic status | Chi squared test | 1.43 * 10−5 | 9.68 * 10−4 |
Biopsy time | Chi squared test | 2.20 * 10−5 | 9.68 * 10−4 |
Cohort | Chi squared test | 2.86 * 10−5 | 9.68 * 10−4 |
Tumor stage | Chi squared test | 3.34 * 10−5 | 9.68 * 10−4 |
HLA_DPA2 | Chi squared test | 1.23 * 10−4 | 2.84 * 10−4 |
Tumor site | Chi squared test | 3.12 * 10−4 | 4.71 * 10−4 |
Mutation count | Kruskal–Wallis test | 3.76 * 10−4 | 4.71 * 10−4 |
Disease free status | Chi squared test | 4.02 * 10−4 | 4.71 * 10−4 |
Cancer type detailed | Chi squared test | 4.11 * 10−4 | 4.71 * 10−4 |
Oncotree code | Chi squared test | 4.11 * 10−4 | 4.71 * 10−4 |
HLA_DPB2 | Chi squared test | 4.70 * 10−4 | 4.71 * 10−4 |
Durable clinical benefit | Chi squared test | 4.87 * 10−4 | 4.71 * 10−4 |
RAF_RAS status | Chi squared test | 6.57 * 10−4 | 5.49 * 10−4 |
HLA_DQA2 | Chi squared test | 6.68 * 10−4 | 5.49 * 10−4 |
HLA_DRB2 | Chi squared test | 7.09 * 10−4 | 5.49 * 10−4 |
Neo-antigen load | Kruskal–Wallis test | 1.24 * 10−3 | 9.02 * 10−4 |
Serum lactate dehydrogenase | Kruskal–Wallis test | 1.75 * 10−3 | 0.012 |
Dosage | Chi squared test | 2.76 * 10−3 | 0.0178 |
Mutation load | Kruskal–Wallis test | 3.62 * 10−3 | 0.021 |
Treatment response | Chi squared test | 3.82 * 10−3 | 0.0211 |